JOINN Laboratories Ocular

JOINN’s Ophthalmology Laboratories

JOINN’s ophthalmology laboratories were established in 2012 and GLP compliant studies are performed by a 35+ person scientific team. The JOINN ocular team has completed over 500 studies and generated data for 30 IND submissions. The facility is AAALAC accredited, inspected by the US FDA, PMDA and MFDS for GLP services and certified by NMPA, OECD and CNAS/ILAC-MRA. 

JOINN Laboratories have deep expertise in ocular disease models and efficacy, tolerance and PK studies for ocular therapies. The JOINN team has supported early discovery through phase I clinical studies including GLP toxicology programs. The team combines comprehensive dosing techniques and specialized surgical procedures with state-of-the-art ocular imaging technology, tissue collection and histopathology analysis.

On This Page

Ocular Disease Models

JOINN offers a broad array of ocular disease models including:

Endpoint Analysis

The ocular team performs various endpoint assessments across rodents, rabbits and primate models using specialized equipment. Optical coherence tomography (OCT) and fundus imaging are used to visually examine the eye tissues in response to stimuli and therapeutic intervention and electreretinogram (ERG) testing is used to measure the electrical activity of the retina in response to light. Measurement of intraocular pressure (IOP) in rabbit and primate eyes are performed to evaluate glaucoma models.
Corneal Wound Model
Figure 1: the corneal wound model in rabbits used to test topical application of recombinant hEGF for wound healing.
OcularB2
Figure 2: Image analyses of normal and treated primate and rabbit eyes
Additional endpoints include IVIS imaging in rodent eyes to evaluate gene expression and distribution.
Example of IVIS Use in a Rat Eye, Auto Florescene After Gene Therapy in a Mouse Eye
Figure 3: IVIS imaging in rat and mouse eyes.

Connect to the Global Liaison Team for more information regarding conducting studies JOINN/China.

Our global liaison team paves the way to extended resources, abundant pharmacology models and budget friendly options seamlessly.